You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Large and middle hepatitis B surface antigen: the lower the better?
View Full Text

http://dx.doi.org/10.1136/gutjnl-2018-316030

Statistics from Altmetric.com

    Footnotes

    • Contributors HHL and TCT drafted the manuscript. JHK did the critical review of the manuscript.

    • Funding This work was supported by the grants from the Ministry of Science and Technology, Executive Yuan, Taiwan (MOST 105-2314-B-303-008).

    • Competing interests JHK is the consultant for Abbvie, Bristol-Myers Squibb and Gilead Sciences; on speaker’s bureau for Abbvie, Bristol-Myers Squibb, Gilead Sciences and Merck.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.